PROCEPT BioRobotics (PRCT)
(Delayed Data from NSDQ)
$37.39 USD
-0.64 (-1.68%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $37.51 +0.12 (0.32%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
PRCT 37.39 -0.64(-1.68%)
Will PRCT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PRCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRCT
ISRG Stock Down More than 13% in 3 Months: How to Play the Stock?
SP Platform's 88% Procedure Growth: The Next Frontier for ISRG?
PRCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
PROCEPT BioRobotics Corporation (PRCT) Reports Q2 Loss, Lags Revenue Estimates
AxoGen (AXGN) Beats Q2 Earnings and Revenue Estimates
Si-Bone (SIBN) Reports Q2 Loss, Beats Revenue Estimates
Other News for PRCT
Is PRCT setting up for a drop? New 52 Week Low shows up after sliding 1.68%
NR7 appears for PRCT after 2.01% move
PRCT Fell Below 20 Day Moving Average on September 17
PROCEPT BioRobotics Updates Executive Severance Agreements
Is PRCT set to rally? Crossed Above 20 Day Moving Average shows up after climbing 4.13%